Izotropic Closes Non-Brokered Private Placement
Izotropic Closes Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - September 20, 2023) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a medical device company commercializing IzoView, a CT (computed tomography) imaging system, that produces images of anatomy for non-invasive tissue characterization with the first application in breast imaging, announced today that, further to its news release on September 13, 2023, that it has completed a non-brokered private placement financing (the "Offering") of 2,841,325 units of the Company (each, a "Unit") at a price of $0.25 per Unit for gross proceeds of $710,331.25. Each Unit consists of one common share and one transferable warrant (each, a "Warrant"), and each Warrant entitles the holder to purchase one additional share at a price of $0.50 per share for a period of two years from closing of the Offering.
溫哥華，不列顛哥倫比亞省-(Newsfile Corp.-2023年9月20日)-Izotrotic公司(CSE：ISO)(OTCQB：IZOZF)(FSE：1R3)(“各向同性“或”公司IzoView是一家正在商業化的醫療設備公司，IzoView是一種CT(電腦斷層成像)成像系統，可以產生解剖圖像，用於非侵入性組織定徵，首次應用於乳房成像。該公司今天宣佈，繼2023年9月13日發佈的新聞稿後，它已經完成了一項非經紀私募融資(The供奉“)，共2,841,325個單位(每個單位，一個”單位)，每單位價格為0.25美元，總收益為710,331.25美元。每個單位包括一股普通股和一份可轉讓認股權證(每份，一份)搜查令“)，而每份認股權證持有人有權在發售結束後兩年內，按每股0.50美元的價格購入額外一股股份。
The use of proceeds from the Offering will be used for general working capital, including paying interest and eliminating $50,000 in debt from promissory notes, and payments for the Company's annual year-end audit and accounting and compliance related items.
此次發行所得資金將用於一般營運資金，包括支付利息和消除本票債務50,000美元，以及支付公司年度年終審計、會計和合規相關專案的費用。
No fees or commissions were paid in connection with the private placement. Costs associated with managing the financing and its closing were mitigated by completing this work in house.
沒有支付與私募有關的費用或佣金。通過在內部完成這項工作，減少了與管理融資和完成融資相關的成本。
All securities issued in connection with the Offering will be subject to a statutory hold period of four months and one day from the date of issuance in accordance with applicable securities legislation.
根據適用的證券法規，所有與發行相關的證券將受自發行之日起計4個月零1天的法定持有期的限制。
None of the securities issued in the Offering will be registered under the United States Securities Act of 1933, as amended (the "1933 Act"), and none of them may be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the 1933 Act. This news release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of the securities in any state where such offer, solicitation, or sale would be unlawful.
在此次發行中發行的任何證券都不會根據修訂後的1933年《美國證券法》(下稱《1933年法案》)進行註冊，而且如果沒有註冊或獲得適用於1933年法案註冊要求的豁免，這些證券都不能在美國發行或出售。本新聞稿不應構成出售要約或邀請購買要約，也不應在任何這樣的要約、招攬或出售將是非法的任何州出售證券。
ON BEHALF OF THE BOARD
我代表董事會
Mr. Robert Thast, CEO
Cell: 604-220-5031
首席執行官Robert Tast先生
電話：604-220-5031
Contact:
Email: info@izocorp.com
Toll Free: 1-833-IZOCORP ext.1
聯繫方式：
電子郵件：info@izocorp.com
免費電話：1-833-IZOCORP分機1
About Izotropic
關於等方向性
More information about Izotropic Corporation can be found on its website at izocorp.com and by reviewing its profile on SEDAR at sedar.com.
欲瞭解有關Izotroy公司的更多資訊，請訪問公司網站：izocorp.com，或查看公司在SEDAR上的簡介：sedar.com。
Forward-Looking Statements
前瞻性陳述
This document may contain statements that are "Forward-Looking Statements," which are based upon the current estimates, assumptions, projections, and expectations of the Company's management, business, and its knowledge of the relevant market and economic environment in which it operates. The Company has tried, where possible, to identify such information and statements by using words such as "anticipate," "believe," "envision," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," "contemplate" and other similar expressions and derivations thereof in connection with any discussion of future events, trends or prospects or future operating or financial performance, although not all forward-looking statements contain these identifying words.
本文檔可能包含“前瞻性陳述”，這些陳述基於對公司管理層、業務的當前估計、假設、預測和預期，以及對公司運營所處的相關市場和經濟環境的瞭解。在可能的情況下，本公司已嘗試通過使用下列詞語來識別此類資訊和陳述：“預期”、“相信”、“設想”、“估計”、“預期”、“打算”、“可能”、“計劃”、“預測”、“專案”、“目標”、“潛在”、“將”、“將”、“可能”、“可能”、“應該”、“繼續，關於未來事件、趨勢或前景或未來經營或財務業績的任何討論，“考慮”及其他類似表述及其派生，儘管並不是所有前瞻性表述都包含這些識別詞語。
These statements are not guarantees of performance and involve risks, including those related to capital requirements and uncertainties that are difficult to control or predict, and as such, they may cause future results of the Company's activity to differ significantly from the content and implications of such statements. Forward-Looking Statements are pertinent only as of the date on which they are made, and the Company undertakes no obligation to update or revise any Forward-Looking Statements to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law. Neither the Company nor its shareholders, officers, and consultants shall be liable for any action and the results of any action taken by any person based on the information contained herein, including, without limitation, the purchase or sale of Company securities. Nothing in this document should be deemed to be medical or other advice of any kind. All images are for illustrative purposes only. IzoView is not yet approved for sale.
這些陳述不是對業績的保證，涉及風險，包括與資本要求和難以控制或預測的不確定性有關的風險，因此，它們可能導致公司未來活動的結果與此類陳述的內容和影響大不相同。前瞻性陳述僅在作出之日起具有相關性，公司沒有義務更新或修改任何前瞻性陳述，以反映新的資訊或未來事件或情況的發生，除非法律另有要求。本公司及其股東、高級管理人員和顧問均不對任何人根據本文所含資訊採取的任何行動以及任何行動的結果負責，包括但不限於購買或出售公司證券。本文檔中的任何內容都不應被視為任何類型的醫療或其他建議。所有圖片僅用於說明目的。IzoView尚未獲準出售。
THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES FOR DISSEMINATION IN THE UNITED STATES
本新聞稿不提供給美國新聞通訊社在美國境內傳播
To view the source version of this press release, please visit
要查看本新聞稿的源版本，請訪問
譯文內容由第三人軟體翻譯。